Samsung will manufacture commercial drug substances and drug product for BMS biologics
Bristol-Myers Squibb and Samsung BioLogics are to increase the scope of a manufacturing collaboration that was first announced in July 2013.
In the new agreement, Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site in South Korea.
Financial terms of the agreement have not been disclosed.
In the first agreement, the two companies collaborated to produce a single commercial antibody drug substance.
'The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients,' said Lou Schmukler, President, Global Manufacturing & Supply at Bristol-Myers Squibb.
'Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production,' said T H Kim, President and CEO of Samsung BioLogics.
Samsung's fully-integrated production facilities offer process development, drug substance manufacturing, and drug product fill and finish services at one location. The company is currently building a second biologics facility, also in Incheon, which is expected to be completed in early 2015.